Comparison · NCT04497987-sae
4200mg Bamlanivimab vs Placebo: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. 4200mg Bamlanivimab vs Placebo: serious adverse events. Trial comparisons, record NCT04497987-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04497987-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0663 | 0.0489 | 0.0894 | wilson | |
| Risk in group 2 | 0.0511 | 0.036 | 0.072 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0152 | -0.012 | 0.0428 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.3 | 0.818 | 2.06 | log | |
| Odds ratio, group 1 over group 2 | 1.32 | 0.808 | 2.15 | log | |
| Number needed to harm, for one more participant with a serious adverse event on 4200mg Bamlanivimab than on Placebo | 65.7 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | 4200mg Bamlanivimab | Participants received single IV infusion of 4200mg bamlanivimab. | 39 | 588 | EG001 |
| Group 2 | Placebo | Participants received single IV infusion of Placebo. | 30 | 587 | EG000 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- Baseline, up to 9 Months
Source ClinicalTrials.gov
Trial
- Title
- A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Preventing SARS-CoV-2 Infection and COVID-19 in Nursing Home Residents and Staff
- NCT number
- NCT04497987
- Phases
- PHASE3
- Conditions
- COVID-19, SARS-CoV2
- Interventions
- Bamlanivimab, Placebo, Etesevimab
- Lead sponsor
- Eli Lilly and Company
- Results first posted
- 2022-02-04
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT04497987?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT04497987-sae